By Haley Nicholson
This year Congress and the administration have found rare bipartisan agreement on prescription drugs.
Congressional committees have held dozens of hearings on prescription drug pricing and transparency and worked together on what can be done to address both.
Several committees have also called in stakeholders from CEOs of pharmaceutical companies to those involved in negotiating prices with insurers.
The administration continues to introduce a variety of proposals pushing back on pharmaceutical companies, pharmacy benefit managers (PBMs) and drug manufacturers on the way they do business.
In all these proposals there is a common theme, finding ways to help drive down costs for consumers and allowing them to be more informed of how much they should anticipate spending at the pharmacy.
In all this federal activity it’s hard to keep track of what has been proposed. What legislation has been introduced? What has passed? Who are the congressional leaders on these topics? And more importantly, what are the chances of movement on any of them? Click here to get a breakdown from the past few months.”
Haley Nicholson is policy director, health, in NCSL’s State-Federal Program